2 results
Approved WMOCompleted
To determine the feasibility, toxicity and safety of anti-CEA x anti hapten bispecific antibodies (TF2) and Lu-177-labelled di-HSG-DOTA peptide (IMP-288) in patients with advanced colorectal carcinoma.
Approved WMOCompleted
Primary Objective** To compare the PFS of melflufen plus dexamethasone (Arm A) versus pomalidomide plus dexamethasone (Arm B) as assessed by the Independent Review Committee (IRC) according to the International Myeloma Working Group Uniform Response…